Although huge emphasis has been put on the capabilities and benefits of using NPs in delivery of STAT to cancer cells, it has been reported that only 0.7% of administered NPs are found to be delivered to the tumor site, thereby challenging the potential role of NPs in drug delivery [271]. The gene discussed is SOAT1; the disease is neoplasm.